Oncotarget is an all-around news-feed dedicated to all things related to Oncology. What makes Oncotagret stand out is the peer review aspect of this online journal publication. All of the content on Oncotaget is concise and well researched information. Through such expertise, Oncotarget has been able to supply a platform that enables its readers with rich and insightful content. Oncotarget is essentially a conglomerate of authors and publishers who come together to discuss cancer research. Oncotarget is geared towards all things pertaining to cancer research. What make the publications of Oncotarget so special is they are able to assessed and reviewed by professionals in the same field. This leaves little room for error. With that being said, Oncotarget can be found on various social media sites such as Facebook, Twitter, Youtube, Google+, and Instagram. For those unaware, Oncology pertains to the study and treatment of cancer. Those interested in partaking in the study of Oncology focus on diagnosing, treating, and taking preventative measures in curing cancer. Prevention can be done by eliminating risky behaviors such as drug abuse and the usage of tobacco and alcohol. Screening patients provides a means to diagnose cancer patients at an early stage, well before it could become a life threatening situation. Another way to retard the possibility of developing cancer is by eating healthy and exercising regularly. The human body in many cases is similar to a vehicle. It requires maintenance.
The editor-in-chief of Oncotarget is Mikhail Blagoskolonny. Currently, Blagoskolonny is a professor at Roswell Park Cancer. He has been there since 2009. Mikhail Blagoskolonny specializes in the fields of Life-Extension and Oncology. In particular, Blagoskolonny’s hypothesis on a popular cancer fighting drug known as rapamycin is noteworthy. Rapamycin is fairly popular in the fight against cancer because it assists cancer patients in the area of life extension. In all, Oncotarget has proven itself as relevant by innovating and revolutionizing the areas of cancer research. View his LinkedIn profile.